RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity
Abstract Background Endocrine-resistant breast cancers have elevated expression of XBP1, where it drives endocrine resistance by controlling the expression of its target genes. Despite the in-depth understanding of the biological functions of XBP1 in ER-positive breast cancer, effectors of endocrine...
Main Authors: | David Barua, Afrin Sultana, Md Nahidul Islam, Fergus Cox, Ananya Gupta, Sanjeev Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-023-10745-1 |
Similar Items
-
miRNA-378 Is Downregulated by XBP1 and Inhibits Growth and Migration of Luminal Breast Cancer Cells
by: Vahid Arabkari, et al.
Published: (2023-12-01) -
Triazoloacridone C-1305 impairs XBP1 splicing by acting as a potential IRE1α endoribonuclease inhibitor
by: Sylwia Bartoszewska, et al.
Published: (2021-03-01) -
IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
by: Keita Sasa, et al.
Published: (2021-11-01) -
Spliced or Unspliced, That Is the Question: The Biological Roles of XBP1 Isoforms in Pathophysiology
by: Xinxin Luo, et al.
Published: (2022-03-01) -
Roles of XBP1s in Transcriptional Regulation of Target Genes
by: Sung-Min Park, et al.
Published: (2021-07-01)